Paola Lucidi1, Francesca Porcellati1, Geremia B Bolli1, Carmine G Fanelli2. 1. Department of Medicine, Section of Endocrinology and Metabolic Diseases, University di Perugia, Piazzale Gambuli, 1, 06132, Perugia, Italy. 2. Department of Medicine, Section of Endocrinology and Metabolic Diseases, University di Perugia, Piazzale Gambuli, 1, 06132, Perugia, Italy. carmine.fanelli@unipg.it.
Abstract
PURPOSE OF REVIEW: In addition to assisting in achieving improved glucose control, continuous glucose monitoring (CGM) sensor technology may also aid in detection and prevention of hypoglycemia. In this paper, we report on the current scientific evidence on the effectiveness of this technology in the prevention of severe hypoglycemia and hypoglycemia unawareness. RECENT FINDINGS: Recent studies have found that the integration of CGM with continuous subcutaneous insulin infusion (CSII) therapy, a system known as sensor-augmented pump (SAP) therapy, very significantly reduces the occurrence of these conditions by providing real-time glucose readings/trends and automatically suspending insulin infusion when glucose is low (LGS) or, even, before glucose is low but is predicted to soon be low (PLGS). Initial data indicate that even for patients with type 1 diabetes treated with multiple daily injections, real-time CGM alone has been found to reduce both severe hypoglycemia and hypoglycemia unawareness. Closed loop systems (artificial pancreas) comprised of CGM and CSII without patient intervention to adjust basal insulin, which automatically reduce, increase, and suspend insulin delivery, represent a potential new option that is moving toward becoming a reality in the near future. Sensor technology promises to continue to improve patients' lives not only by attaining glycemic control but also by reducing hypoglycemia, a goal best achieved in conjunction with structured individualized patient education.
PURPOSE OF REVIEW: In addition to assisting in achieving improved glucose control, continuous glucose monitoring (CGM) sensor technology may also aid in detection and prevention of hypoglycemia. In this paper, we report on the current scientific evidence on the effectiveness of this technology in the prevention of severe hypoglycemia and hypoglycemia unawareness. RECENT FINDINGS: Recent studies have found that the integration of CGM with continuous subcutaneous insulin infusion (CSII) therapy, a system known as sensor-augmented pump (SAP) therapy, very significantly reduces the occurrence of these conditions by providing real-time glucose readings/trends and automatically suspending insulin infusion when glucose is low (LGS) or, even, before glucose is low but is predicted to soon be low (PLGS). Initial data indicate that even for patients with type 1 diabetes treated with multiple daily injections, real-time CGM alone has been found to reduce both severe hypoglycemia and hypoglycemia unawareness. Closed loop systems (artificial pancreas) comprised of CGM and CSII without patient intervention to adjust basal insulin, which automatically reduce, increase, and suspend insulin delivery, represent a potential new option that is moving toward becoming a reality in the near future. Sensor technology promises to continue to improve patients' lives not only by attaining glycemic control but also by reducing hypoglycemia, a goal best achieved in conjunction with structured individualized patient education.
Authors: Thomas Danne; Christiana Tsioli; Olga Kordonouri; Sarah Blaesig; Kerstin Remus; Anirban Roy; Barry Keenan; Scott W Lee; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2014-01-21 Impact factor: 6.118
Authors: C Abraira; W G Henderson; J A Colwell; F Q Nuttall; J P Comstock; N V Emanuele; S R Levin; C T Sawin; C K Silbert Journal: Diabetes Care Date: 1998-04 Impact factor: 19.112
Authors: Ana María Gómez; Lisseth Fernanda Marín Carrillo; Oscar Mauricio Muñoz Velandia; Martín Alonso Rondón Sepúlveda; Carol M Arévalo Correa; Edwin Mora Garzón; Maria Camila Cuervo Diaz; Diana Cristina Henao Carrillo Journal: Diabetes Technol Ther Date: 2016-12-21 Impact factor: 6.118
Authors: Marcos Pazos-Couselo; Jose Manuel García-López; Maria González-Rodríguez; Francisco Gude; Jose Manuel Mayán-Santos; Santiago Rodríguez-Segade; Javier Rodríguez-García; Felipe Casanueva Journal: Can J Diabetes Date: 2015-08-05 Impact factor: 4.190
Authors: Richard M Bergenstal; David C Klonoff; Satish K Garg; Bruce W Bode; Melissa Meredith; Robert H Slover; Andrew J Ahmann; John B Welsh; Scott W Lee; Francine R Kaufman Journal: N Engl J Med Date: 2013-06-22 Impact factor: 91.245
Authors: Scott J Pilla; Jenny Park; Jessica L Schwartz; Michael C Albert; Patti L Ephraim; L Ebony Boulware; Nestoras N Mathioudakis; Nisa M Maruthur; Mary Catherine Beach; Raquel C Greer Journal: J Gen Intern Med Date: 2021-01-21 Impact factor: 6.473